PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35252694-1	2022	Exploration of alternate solid forms for dasatinib, a potent oncogene tyrosine kinase inhibitor classified under Biopharmaceutics Classification System (BCS) class II drugs with low water solubility and high permeability, has been performed using COSMO-RS excess enthalpy (Hex) to increase dissolution.	Dasatinib	41-50	hematopoietically expressed homeobox	Homo sapiens	273-276	
22874537-0	2012	Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes.	Dasatinib	0-9	hematopoietically expressed homeobox	Homo sapiens	57-60	
22874537-0	2012	Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes.	Dasatinib	0-9	hematopoietically expressed homeobox	Homo sapiens	61-65	
22874537-3	2012	Here we show that the BCR-ABL/Src kinase inhibitor dasatinib decreases PRH phosphorylation and increases PRH-dependent repression of Vegf and Vegfr-1.	Dasatinib	51-60	hematopoietically expressed homeobox	Homo sapiens	71-74	
22874537-3	2012	Here we show that the BCR-ABL/Src kinase inhibitor dasatinib decreases PRH phosphorylation and increases PRH-dependent repression of Vegf and Vegfr-1.	Dasatinib	51-60	hematopoietically expressed homeobox	Homo sapiens	105-108	
22874537-5	2012	Thus the re-establishment of gene control by PRH is in part responsible for the therapeutic effects of dasatinib.	Dasatinib	103-112	hematopoietically expressed homeobox	Homo sapiens	45-48